Psychopharmacology

, Volume 180, Issue 4, pp 743–751

Examining the neural targets of the AMPA receptor potentiator LY404187 in the rat brain using pharmacological magnetic resonance imaging

  • Nicholas Jones
  • Michael J. O’Neill
  • Mark Tricklebank
  • Vincenzo Libri
  • Steve C. R. Williams
Original Investigation

Abstract

Rationale

Drugs that enhance α-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptor-mediated glutamatergic transmission, such as the AMPA receptor potentiator LY404187, may form treatment strategies for disorders of cognition, learning and memory.

Objectives

Pharmacological magnetic resonance imaging (phMRI) uses blood oxygenation level dependent (BOLD) contrast as a marker of neuronal activity and allows dynamic non-invasive in vivo imaging of the effects of CNS-active compounds. This study used phMRI to examine the effects of LY404187 in the rat brain.

Method

Groups of Sprague Dawley rats (n=7) were anaesthetised and placed in a 4.7 Tesla superconducting magnet before receiving an acute dose of LY404187 (0.5 mg/kg s.c.), either alone or after pretreatment with the selective AMPA/kainate antagonist LY293558 (15 mg/kg s.c.), or LY293558 alone (15 mg/kg s.c.). Brain images were acquired for each subject every minute for 180 min. These volumes were extensively pre-processed before being analysed for changes in BOLD contrast.

Results

LY404187 produced significant increases in BOLD contrast in brain regions including the hippocampus, lateral and medial habenulae and superior and inferior colliculi. These changes were blocked by LY293558. When administered alone, LY293558 caused widespread decreases in BOLD contrast.

Conclusions

The known actions of LY404187 suggest the observed BOLD signal increases reflect increases in excitatory neurotransmission. The decreases in signal following LY293558 alone are harder to interpret and are discussed in terms of the negative BOLD response. This study provides the first evidence that the effects of AMPA receptor-mediating compounds can be observed using phMRI.

Keywords

LY404187 LY293558 AMPA Memory Cognition Glutamate MRI Rat 

References

  1. Aguirre GK, Zarahn E, D’Esposito M (1998) The inferential impact of global signal covariates in functional neuroimaging analyses. NeuroImage 8:302–306CrossRefPubMedGoogle Scholar
  2. Alt A, Weiss B, Ogden AM, Knauss JL, Oler J, Ho K, Large TH, Bleakman D (2004) Pharmacological characterization of glutamatergic agonists and antagonists at recombinant human homomeric and heteromeric kainate receptors in vitro. Neuropharmacology 46:793–806CrossRefPubMedGoogle Scholar
  3. Bandettini PA, Wong EC, Hinks RS, Tikofsky RS, Hyde JS (1992) Time course EPI of human brain function during task activation. Magn Reson Med 25:390–397PubMedCrossRefGoogle Scholar
  4. Baumbarger P, Muhlhauser M, Yang CR, Nisenbaum ES (2001a) LY392098, a novel AMPA receptor potentiator: electrophysiological studies in prefrontal cortical neurons. Neuropharmacology 40:992–1002CrossRefPubMedGoogle Scholar
  5. Baumbarger PJ, Muhlhauser M, Zhai J, Yang CR, Nisenbaum ES (2001b) Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in prefrontal cortical pyramidal neurons by a novel allosteric potentiator. J Pharmacol Exp Ther 298:86–102PubMedGoogle Scholar
  6. Berg-Johnsen J, Langmoen IA (1992) The effect of isoflurane on excitatory synaptic transmission in the rat hippocampus. Acta Anaesthesiol Scand 36:350–355PubMedCrossRefGoogle Scholar
  7. Bleakman D, Schoepp DD, Ballyk B, Bufton H, Sharpe EF, Thomas K, Ornstein PL, Kamboj RK (1996) Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4AR,6R,8AR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3 carboxylic acid. Mol Pharmacol 49:581–585PubMedGoogle Scholar
  8. Bleakman D, Ogden AM, Ornstein PL, Hoo K (1999) Pharmacological characterization of a GluR6 kainate receptor in cultured hippocampal neurons. Eur J Pharmacol 378:331–337CrossRefPubMedGoogle Scholar
  9. Brett M, Anton J-L, Valabreque R, Poline J-P (2002) Region of interest analysis using an SPM toolbox. Abstract presented at the 8th International Conference on Functional Mapping of the Human Brain, 2–6 June 2002, Sendai, Japan. Available on CD-ROM in NeuroImage, vol 16, no 2Google Scholar
  10. Browne SE, McCulloch J (1994) AMPA receptor antagonists and local cerebral glucose utilization in the rat. Brain Res 641:10–20CrossRefPubMedGoogle Scholar
  11. Burdett NG, Menon DK, Carpenter TA, Jones JG, Hall LD (1995) Visualisation of changes in regional cerebral blood flow (rCBF) produced by ketamine using long TE gradient-echo sequences: preliminary results. Magn Reson Imaging 13:549–553CrossRefPubMedGoogle Scholar
  12. Cash D, Read SJ, Lythgoe D, Williams SCR, Roberts TJ, Ireland MD, Smart SC, Hunter AJ (2003) Autoradiographic and functional MRI assessment of rat brain response to amphetamine under halothane and a-chloralose anaesthesia. J Cereb Blood Flow Metab 23:S10Google Scholar
  13. Chen YC, Galpern WR, Brownell AL, Matthews RT, Bogdanov M, Isacson O, Keltner JR, Beal MF, Rosen BR, Jenkins BG (1997) Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn Reson Med 38:389–398PubMedCrossRefGoogle Scholar
  14. Czisch M, Wehrle R, Kaufmann C, Wetter TC, Holsboer F, Pollmächer T, Auer DP (2004) Functional MRI during sleep: BOLD signal decreases and their electrophysiological correlates. Eur J Neurosci 20:566–574CrossRefPubMedGoogle Scholar
  15. Fowler JH, Whalley K, Murray TK, Ward MA, Crile R, McKinzie D, O’Neill MJ, McCulloch J (2003) Mapping the anatomical substrates of the cognitive enhancing effects of AMPA receptor potentiators with 14C-2-deoxyglucose autoradiography and c-fos immunocytochemistry. J Cereb Blood Flow Metab 23:S10Google Scholar
  16. Fowler JH, Whalley K, Murray T, O’Neill MJ, McCulloch J (2004) The AMPA receptor potentiator LY404187 increases cerebral glucose utilization and c-fos expression in the rat. J Cereb Blood Flow Metab 24:1098–1109CrossRefPubMedGoogle Scholar
  17. Friston KJ, Frith CD, Liddle PF, Dolan RJ, Lammertsma AA, Frackowick AA (1990) The relationship between global and local changes in PET scans. J Cereb Blood Flow Metab 13:1038–1040Google Scholar
  18. Friston K, Holmes A, Worsley K, Poline J-B, Frith J, Frackowiak R (1995) Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 2:189–210CrossRefGoogle Scholar
  19. Gates M, Ogden A, Bleakman D (2001) Pharmacological effects of AMPA receptor potentiators LY392098 and LY404187 on rat neuronal AMPA receptors in vitro. Neuropharmacology 40:984–991CrossRefPubMedGoogle Scholar
  20. Gaza WC, Ribak CE (1997) Immunocytochemical localization of AMPA receptors in the rat inferior colliculus. Brain Res 774:175–183CrossRefPubMedGoogle Scholar
  21. Harel N, Lee S-P, Nagaoka T, Kim D-S, Kim S-G (2002) Origin of negative blood oxygenation level-dependent fMRI signals. J Cereb Blood Flow Metab 22:908–917CrossRefPubMedGoogle Scholar
  22. Hlustik P, Noll DC, Small SL (1998) Suppression of vascular artefacts in functional magnetic resonance images using MR angiograms. Neuroimage 7:224–231CrossRefPubMedGoogle Scholar
  23. Houston GC, Papadakis NG, Carpenter TA, Hall LD, Mukherjee B, James MF, Huang CL (2001) Mapping of brain activation in response to pharmacological agents using fMRI in the rat. Magn Reson Imaging 19:905–919CrossRefPubMedGoogle Scholar
  24. Kalisch R, Elbel G-K, Gössl C, Czisch M, Auer D (2001) Blood pressure changes induced by arterial blood withdrawal influence BOLD signal in anaesthetised rats at 7 Tesla: implications for pharmacologic MRI. Neuroimage 14:891–898CrossRefPubMedGoogle Scholar
  25. Leslie RA, James MF (2000) Pharmacological magnetic resonance imaging: a new application for functional MRI. Trends Pharmacol Sci 21:314–318CrossRefPubMedGoogle Scholar
  26. Logothetis NK, Pauls J, Augath M, Trinath T, Oeltermann A (2001) Neurophysiological investigation of the basis of the fMRI signal. Nature 412:150–157CrossRefPubMedGoogle Scholar
  27. Lowe AS, Barker GJ, Ireland MD, Beech JS, Williams SCR (2005) Estimating global effects from extra-cerebral tissue: inferential utility for pharmacological fMRI. Magn Reson Med, (in press)Google Scholar
  28. Maclver MB, Mikulee AA, Amagasu SM, Monroe FA (1996) Volatile anaesthetics depress glutamate transmission via presynaptic actions. Anesthesiology 85:823–824CrossRefPubMedGoogle Scholar
  29. Marota JJ, Mandeville JB, Weisskoff RM, Moskowitz MA, Rosen BR, Kosofsky BE (2000) Cocaine activation discriminates dopaminergic projections by temporal response: an fMRI study in rat. Neuroimage 11:13–23CrossRefPubMedGoogle Scholar
  30. Miu P, Jarvie KR, Radhakrishnan V, Gates MR, Ogden A, Ornstein PL, Zarrinmayeh H, Ho K, Peters D, Grabell J, Gupta A, Zimmerman DM, Bleakman D (2001) Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro. Neuropharmacology 40:976–983CrossRefPubMedGoogle Scholar
  31. Ogawa S, Tank DW, Menon R, Ellermann JM, Kim SG, Merkle H, Ugurbil K (1992) Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. Proc Natl Acad Sci U S A 89:5951–5955PubMedCrossRefGoogle Scholar
  32. Ogawa S, Lee TM, Stepnoski R, Chen W, Zhu XH, Ugurbil K (2000) An approach to probe some neural systems interaction by functional MRI at neural time scale down to milliseconds. Proc Natl Acad Sci U S A 97:11026–11031CrossRefPubMedGoogle Scholar
  33. O’Neill MJ, Lees KR (2002) Chapter 13, stroke. In: Danysz W, Lodge D, Parsons CG (eds) Ionotropic glutamate receptors as therapeutic targets. FP Graham, Johnson City, pp 403–447Google Scholar
  34. O’Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES (2004) AMPA receptor potentiators for the treatment of CND disorders. Curr Drug Targets CNS Neurol Disord 3:181–194CrossRefPubMedGoogle Scholar
  35. Paxinos G, Watson C (1982) The rat brain in stereotaxic coordinates. Academic, New YorkGoogle Scholar
  36. Pearce RA, Stringer JL, Lothman EW (1989) Effect of volatile anesthetics on synaptic transmission in the rat hippocampus. Anesthesiology 71:591–598PubMedCrossRefGoogle Scholar
  37. Petersson KM, Nichols TE, Poline JB, Holmes AP (1999) Statistical limitations in functional neuroimaging. I. Non-inferential methods and statistical models. Philos Trans R Soc Lond B Biol Sci 354:1239–1260CrossRefPubMedGoogle Scholar
  38. Petralia RS, Wenthold RJ (1992) Light and electron immunocyctochemical localization of AMPA-selective glutamate receptors in the rat brain. J Comp Neurol 318:329–354CrossRefPubMedGoogle Scholar
  39. Plested AJ, Wildman SS, Lieb WR, Franks NP (2004) Determinants of the sensitivity of AMPA receptors to xenon. Anesthesiology 100:347–358CrossRefPubMedGoogle Scholar
  40. Preece M, Mukherjee B, Huang CL, Hall LD, Leslie RA, James MF (2001) Detection of pharmacologically mediated changes in cerebral activity by functional magnetic resonance imaging: the effects of sulpiride in the brain of the anaesthetised rat. Brain Res 916:107–114CrossRefPubMedGoogle Scholar
  41. Quirk JC, Nisenbaum ES (2002) LY404187: a novel positive allosteric modulator of AMPA receptors. CNS Drug Rev 8:255–282PubMedCrossRefGoogle Scholar
  42. Ragowski MA, Gryder D, Castaneda D, Yonekawa W, Banks MK, Li H (2003) GluR5 kainate receptors, seizures and the amygdala. Ann N Y Acad Sci 985:150–162PubMedCrossRefGoogle Scholar
  43. Rasmussen K, Kendrik WT, Kogan JH, Aghajanian GK (1996) A selective AMPA antagonist, LY293558, suppresses morphine withdrawal-induced activation of locus coeruleus neurons and behavioural signs of morphine withdrawal. Neuropsychopharmacology 15:497–505CrossRefPubMedGoogle Scholar
  44. Roberts TJ (2004) Structural and functional imaging in an experimental model of Huntington’s disease—mapping pathogenesis and potential therapy. Ph.D. thesis, University of LondonGoogle Scholar
  45. Salmeron BJ, Stein EA (2002) Pharmacological applications of magnetic resonance imaging. Psychopharmacol Bull 36:102–129PubMedGoogle Scholar
  46. Schmid S, Guthmann A, Ruppersberg JP, Herbert H (2001) Expression of AMPA receptor subunit flip/flop splice variants in the rat auditory brainstem and inferior colliculus. J Comp Neurol 430:160–171CrossRefPubMedGoogle Scholar
  47. Schoepp DD, Lodge D, Bleakman D, Leander JD, Tizzano JP, Wright RA, Palmer AJ, Salhoff CR, Ornstein PL (1995) In vitro and in vivo antagonism of AMPA receptor activation by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5yl)ethyl]decahydroisoquinoline-3-carboxylic acid. Neuropharmacology 34:1159–1168CrossRefPubMedGoogle Scholar
  48. Shmuel A, Yacoub E, Pfeufer J, Van der Moortele P-F, Adriany G, Hu X, Ugurbil K (2002) Sustained negative BOLD, blood flow and oxygen consumption response and its coupling to the positive response in the human brain. Neuron 36:1195–1210CrossRefPubMedGoogle Scholar
  49. Simmons RMA, Li DL, Hoo KH, Deverill M, Ornstein PL, Iyengar S (1998) Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat. Neuropharmacology 37:25–36CrossRefPubMedGoogle Scholar
  50. Smith S (2002) Fast robust automated brain extraction. Hum Brain Mapp 17:143–155CrossRefPubMedGoogle Scholar
  51. Smith AT, Williams AL, Singh KD (2004) Negative BOLD in the visual cortex: evidence against blood stealing. Hum Brain Mapp 21:213–220CrossRefPubMedGoogle Scholar
  52. Smolders I, Bortolotto ZA, Clarke VRJ, Warre R, Khan GM, O’Neill MJ, Ornstein PL, Bleakman D, Ogden A, Weiss B, Stables JP, Ho KH, Ebinger G, Collingridge GL, Lodge D, Michotte Y (2002) Antagonists of GLU(K5)-containing kainate receptors prevent pilocarpine-induced limbic seizures. Nat Neurosci 5:796–804PubMedGoogle Scholar
  53. Vandergriff J, Huff K, Bond A, Lodge D (2001) Potentiation of responses to AMPA on central neurones by LY392098 and LY404187 in vivo. Neuropharmacology 40:1003–1009CrossRefPubMedGoogle Scholar
  54. Wenthold RJ, Petralia RS, Blahos J II, Niedzielski AS (1996) Evidence for multiple AMPA receptor complexes in hippocampal CA1/CA2 neurons. J Neurosci 16:1982–1989PubMedGoogle Scholar
  55. Worsley KJ, Friston KJ (1995) Analysis of fMRI time-series revisited—again. Neuroimage 2:173–181CrossRefPubMedGoogle Scholar
  56. Xu H, Li SJ, Bodurka J, Zhao X, Xi ZX, Stein EA (2000) Heroin-induced neuronal activation in rat brain assessed by functional MRI. Neuroreport 11:1085–1092PubMedCrossRefGoogle Scholar
  57. Yamada KA (2000) Therapeutic potential of positive AMPA receptor modulators in the treatment of neurological disease. Expert Opin Investig Drugs 9:765–768CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Nicholas Jones
    • 1
  • Michael J. O’Neill
    • 2
  • Mark Tricklebank
    • 2
  • Vincenzo Libri
    • 3
  • Steve C. R. Williams
    • 1
  1. 1.Neuroimaging Research GroupInstitute of PsychiatryLondonUK
  2. 2.Eli Lilly and Co. Ltd.WindleshamUK
  3. 3.Neurology Centre of Excellence in Drug DiscoveryGlaxoSmithKlineHarlowUK

Personalised recommendations